BIIB - AAIC 2021: What to look for at Alzheimer's biggest annual conference

knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to major stock swings. This year's conference comes less than two months after the FDA approval of the first Alzheimer's disease-modifying therapy, Biogen's (BIIB) Aduhelm (aducanumab). Here's a look at companies and drug candidates that should be on investors' radar next week.  Eisai Biogen's partner on Aduhelm, Eisai (ESALF), is scheduled to make 11 presentations at the conference. The one likely to garner the most attention is on the amyloid-beta targeting antibody lecanemab. The company will present a preliminary assessment of phase 2b data following 18 months of treatment with lecanemab in early Alzheimer's. Preliminary screening and baseline characteristics for a phase 3 study in preclinical Alzheimer's will also be

For further details see:

AAIC 2021: What to look for at Alzheimer's biggest annual conference